MedPath

Lovaza

These highlights do not include all the information needed to use LOVAZA safely and effectively. See full prescribing information for LOVAZA. LOVAZA® (omega-3-acid ethyl esters) Capsules Initial U.S. Approval: 2004

Approved
Approval ID

fb2141cd-6cff-470c-b776-4482afcebb41

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Sep 8, 2009

Manufacturers
FDA

Physicians Total Care, Inc.

DUNS: 194123980

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

omega-3-acid ethyl esters

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code54868-5816
Application NumberNDA021654
Product Classification
M
Marketing Category
C73594
G
Generic Name
omega-3-acid ethyl esters
Product Specifications
Route of AdministrationORAL
Effective DateFebruary 15, 2011
FDA Product Classification

INGREDIENTS (5)

OMEGA-3-ACID ETHYL ESTERSActive
Quantity: 1 g in 1 1
Code: D87YGH4Z0Q
Classification: ACTIB
ALPHA-TOCOPHEROLInactive
Code: H4N855PNZ1
Classification: IACT
GELATINInactive
Code: 2G86QN327L
Classification: IACT
WATERInactive
Code: 059QF0KO0R
Classification: IACT
GLYCERINInactive
Code: PDC6A3C0OX
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Lovaza - FDA Drug Approval Details